Cannabidiol isn't the only ingredient in products marketed as dietary supplements that US regulators say shouldn't be offered as treatment for opioid addiction. The Food and Drug Administration also recently warned EPH Technologies Inc. about opioid withdrawal treatment claims for its Detoxoplex supplement.
The Aztec, NM, firm apparently heeded the FDA's 18 November warning, which also noted violative drug and disease claims for its Sinoplex and Migrenza nasal sprays. EPH continued selling other supplements on its website 2 December, but the three that the Center for Drug Evaluation and Research's Office of Unapproved Drugs and Labeling Compliance cited in the
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?